AI Article Synopsis
- The study compared adjuvant chemotherapy alone (Group 1) with adjuvant chemotherapy plus tumor-infiltrating lymphocytes (TILs) therapy (Group 2) in osteosarcoma patients who did not respond well to neoadjuvant chemotherapy.
- Patients receiving TILs therapy showed significantly better disease-free survival (DFS) and overall survival (OS) compared to those without TILs, with median DFS of 65.3 months vs. 55.5 months and median OS of 95.8 months vs. 80.4 months.
- The analysis found that the number of TILs transfused was a key independent factor associated with improved survival outcomes, suggesting that combining
Article Abstract
To investigate the efficacy of adjuvant chemotherapy plus tumor-infiltrating lymphocytes (TILs) therapy in osteosarcoma patients with a poor response to neoadjuvant chemotherapy. 40 patients received adjuvant chemotherapy (Group 1) and 40 patients received adjuvant chemotherapy plus TILs therapy (Group 2). Disease-free survival (DFS) and overall survival (OS) were analyzed by Kaplan-Meier analysis. The median DFS (mDFS; 65.3 months) and median OS (mOS; 95.8 months) in Group 2 were significantly prolonged compared with those in Group 1 (55.5 months for mDFS and 80.4 months for mOS). Univariate and multivariate analyses indicated that a greater number of TILs transfused was an independent prognostic factor for both mDFS and mOS. Adjuvant chemotherapy plus TILs therapy may prolong survival of patients with a poor response to neoadjuvant chemotherapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2020-0107 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!